



JUN 21 2004 11:27AM

AVENTIS US PAT DEPT

NO. 4394 P. 1

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:  
**FRA V2002/0026 US NP**

Applicants:  
**Pierre Mourier, et al**

Serial No.  
**10/665,872**

Filing Date:  
**September 18, 2003**

Title of Invention:  
**Methods For Determining Specific Groups Constituting  
Heparins Or Low Molecular Weight Heparins**

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, at (703) 746-4060, on

Date of Deposit 6-21-04

Printed Name of Person Signing Certificate Maribel Mendez

Signature Maribel Mendez

**Total Number of Pages Sent: 4**

Attorney: **Joseph Strupczewski**

Group Art Unit: **Not Yet Assigned**

Examiner: **Not Yet Assigned**

TO: Mail Stop **MISSING PARTS**  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,  
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit  
account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

☐ Amendment, 37 CFR \_\_\_\_\_

☐ Charge deposit account, in duplicate

☐ Extension of Time Petition

☐ Issue Fee Transmittal & Advance Order

☐ Maintenance Fee Transmittal

☐ Fee Transmittal

☐ Petition under 37 CFR \_\_\_\_\_

☒ Other **Notice to Comply with  
Requirements For Patent Applications  
Containing Nucleotide Sequence And/Or  
Amino Acid Sequence**

☒ Other **Response to Notice To Comply  
Under 37 CFR 1.821-1.825 To Supply  
Sequence Listing**

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)



JUN 21 2004 11:27AM

AVENTIS US PAT DEPT

NO. 4394 P. 2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Pierre Mourier, et al.**

Examiner: Not Yet Assigned

Application No.: 10/665,872

Art Unit: Not Yet Assigned

Filed: September 18, 2003

Title: **Methods For Determining Specific  
Groups Constituting Heparins Or Low  
Molecular Weight Heparins**

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

6-21-04  
Date of Transmission

Maibet Mendez  
Signature

**RESPONSE TO NOTICE TO COMPLY UNDER 37 CFR. 1.821-  
1.825 TO SUPPLY SEQUENCE LISTING**


Mail Stop Missing Parts  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This correspondence is in response to a notice to comply with requirements for patent applications that contain nucleotide sequences and/or amino acid sequences. No sequence is being submitted as the Initial Patent Examination Division has misinterpreted the content of the above referenced patent application. The present application contains no nucleotides or amino acids. The subject matter of the application concerns polysaccharides (no bases present). In the claims the compounds that are disclosed are designated as disaccharides and trisaccharides. There are no nucleotide or amino acid sequences disclosed. In speaking with a representative of the Initial Patent Examination Division by telephone, the representative indicated that perhaps the designations shown on page 7 of the specification led the Division to believe that nucleotides were present. By way of explanation, the short hand designations found on page 7 such as GlcNAc, Gal, Xyl all represent saccharides. On page 15 of the specification there is a list of these abbreviations and their meaning.

In the event the Initial Patent Examination Division needs further clarification, please call (collect if necessary) the telephone number listed below.

Respectfully submitted,

  
Joseph Strupczewski, Reg. No. 50,903  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2387  
Telefax (908) 231-2626


Aventis Docket No. FRAV2002/0026 US NP



JUN 21 2004 11:27AM

AVENTIS US PAT DE

**BEST AVAILABLE COPY**



**UNITED STATES PATENT AND TRADEMARK OFFICE**

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22304-4450  
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/665,872	09/18/2003	Pierre Mourier	FRA V2003/0066 US APP.

005487  
ROSS J. OEHLER  
AVENTIS PHARMACEUTICALS INC.  
ROUTE 202-206  
MAIL CODE: D303A  
BRIDGEWATER, NJ 08807

**CONFIRMATION NO. 6764**  
**FORMALITIES LETTER**  
\*OC000000012874958\*

Date Mailed: 06/04/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts  
Commissioner for Patents

JUN. 21. 2004 11:28AM

AVENTIS US PAT DEPT

**BEST AVAILABLE COPY**

P. 4  
Page 2 of 2

P.O. Box 1450  
Alexandria VA 22313-1450

---

*A copy of this notice MUST be returned with the reply.*



---

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY